Association of Epidermal Growth Factor Receptor Mutations with Metastatic Presentations in Non-Small Cell Lung Cancer

Table 2

Relationship between clinical factors and EGFR mutations.

Characteristic	Number of patients with EGFR mutations (%)	𝑃	OR in multivariate analysis (95% CI)	𝑃
Age, years		.690	NI
≤63	18 (27)
>63	18 (31)
Gender		<.001		.805
Male	15 (17)		Reference
Female	21 (55)		0.8 (0.1–4.8)
Smoking history		<.001		.020
Yes	12 (15)		Reference
Never	24 (53)		7.7 (1.4–42.8)
Histology		<.001		.005
ADC	32 (40)		9.4 (2.0–41.5)
Others	4 (9)		Reference
Tumor size		.367	NI
Small (≤4.2)	21 (32)
Large (>4.2)	15 (25)
T stage		.616	NI
T1-2	23 (27)
T3-4	13 (32)
N stage		.033		.017
N0–2	30 (35)		Reference
N3	6 (15)		0.2 (0.0–0.7)
M stage		.037	NI
M0	7 (16)
M1	29 (35)
Metastases to pleura		.001
PMME	10 (71)		24.2 (4.1<)	<.001
Non-PMME	2 (15)		0.8 (0.1–5.2)	.783
No	24 (24)		Reference
Metastases to lung		.082	NI
No	21 (24)
Yes	15 (39)
Metastases to brain		.075	NI
No	24 (24)
Yes	10 (43)
Metastases to bone		.121	NI
No	21 (24)
Yes	14 (39)
Metastases to liver		.410	NI
No	33 (28)
Yes	3 (43)
Metastases to other sites		.347	NI
No	34 (31)
Yes	2 (14)

Abbreviations as in Table 1.